EXATECAN FORMULATION

Formulations for treating proliferative disorders have been developed. In some forms, the formulations are in the form of an injectable aqueous solution for treating tumors and contain exatecan mesylate, optionally including an immunostimulatory agent or adjuvant such as an immunostimulatory oligonu...

Full description

Saved in:
Bibliographic Details
Main Authors DIXON, Brian, GIRARDI, Michael, SUH, Heewon, SALTZMAN, W. Mark, LEWIS, Julia
Format Patent
LanguageEnglish
Published 24.10.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Formulations for treating proliferative disorders have been developed. In some forms, the formulations are in the form of an injectable aqueous solution for treating tumors and contain exatecan mesylate, optionally including an immunostimulatory agent or adjuvant such as an immunostimulatory oligonucleotide (CpG), at a pH at which the exatecan is soluble until the pH is raised by contacting normal tissue. In some forms, the formulations contain core-shell particles, containing an exatecan in its free base form, a hydrophobic core, and a shell, coating, or corona containing hyperbranched polyglycerol in which hydroxyl groups of the hyperbranched polyglycerol are converted to aldehydes, to adhere the particles to tissue.
Bibliography:Application Number: AU20230254171